Correction: Thoratec attractive on any post-guidance weakness, says Oppenheimer Oppenheimer reports that Thoratec (THOR) will provide 2013 guidance on February 5, and the firm adds that the company has traditionally been conservative with its first outlook of the year. Oppenheimer thinks the stock may be muted in the near-term but it believes that the shares will have a number of positive catalysts later in the year. It recommends buying the shares on any pullbacks. A previous note incorrectly stated that this note from Oppenheimer was written about HeartWare (HTWR).
News For THOR;HTWR From The Last 14 Days
Check below for free stories on THOR;HTWR the last two weeks.